DE20116346U1 - Micronutrient combination product, among others with vitamins and carotenoids - Google Patents

Description

Reference number Our reference Düsseldorf,

Utility model application OD 40004 / SAM 1 October 2001

ORTHOMOL PHARMACEUTICAL SALES GMBH

ORTHOMOL PHARMAZEUTIC VERTRIEBS GMBH Micronutrient combination product with vitamins and carotenoids

The present invention relates to a micronutrient combination product for supplementary balanced nutrition with, among other things, vitamins and carotenoids.

It is undisputed that vitamins, trace elements, minerals, carotenoids and secondary plant substances, vitaminoids as well as amino and omega-3 fatty acids are of great nutritional importance. It is well known that an insufficient intake of the aforementioned substances leads to deficiency symptoms in both the human and animal organism. The effect of carotenoids and vitamins is often based on antioxidative, radical-scavenging properties, since oxidative agents and radicals are known to lead to cell changes.

SAM:sam

· I

-2-

Vitamins are organic substances that are necessary to maintain the health and performance of the human organism and must be supplied with food. Small daily amounts, which can be in the mg or μg range, are sufficient to regulate the metabolism of carbohydrates, fats and proteins. Each vitamin fulfils special tasks that cannot be performed in the same way by another vitamin. Vitamin-like compounds that are not essential for humans are also known as vitaminoids. Examples of these are carnitine or coenzyme Q10.

The exogenous supply of vitamins must be in a well-balanced ratio to one another and to the requirement, depending on the diet, type, gender, age, medication intake and external environmental conditions. Depending on the type of vitamin that is missing, an inadequate supply of vitamins causes various specific vitamin deficiency diseases, such as avitaminosis or hypovitaminosis. Known diseases are beriberi, scurvy, rickets, pellagra, etc. Given the nutritional situation in modern industrial society, avitaminosis has become rare, but hypovitaminosis can occur as a result of illness, e.g. when the intestinal flora is destroyed by antibiotics or when the diet is unbalanced. In individual cases, symptoms of overdose, so-called hypervitaminosis, can also occur.

When vitamins are administered in concentrations that exceed the usual physiological values, problems with drugs administered at the same time can arise. Drugs can affect the absorption and metabolism of vitamins, or the vitamins can change the pharmacological properties of the drugs.

Carotenoids have a basic structure of eight isoprene units. In the plant organism, carotenoids serve as light filters and are involved in the energy transfer during photosynthesis. Their function as provitamins is important for the animal organism, for example carotenoids are precursors of the retina and are therefore important for the visual process. In pharmaceutical preparations, carotenoids are used as vitamin A precursors. Their properties as antioxidants are used as a supplementary dietary treatment.

certain types of cancer.

Oral administration of high amounts of beta-carotene to smokers can cause harm.

For the long-term treatment of cardiovascular diseases such as arteriosclerosis, cardiac arrhythmias and heart failure, drugs or drug combinations are usually administered over several weeks, months or even years. Depending on the disease, such drugs are often administered for life. It is well known that many of the drugs administered to treat heart diseases have mild to severe side effects.

Many of the cardiovascular drugs commonly prescribed in practice can lead to deficiencies in vital substances such as vitamins, trace elements, minerals, carotenoids, secondary plant substances, vitaminoids and/or amino and omega-3 fatty acids. Synthetic pharmaceuticals can hinder the absorption of vital substances in the intestine, but they can also accelerate their metabolism and excretion via urine. This can often lead to vital substance deficiencies that negatively affect the existing heart disease.

Diuretics, i.e. water-reducing agents, are used for heart disease and high blood pressure. These increase urine production and therefore lead to increased excretion of vital substances, particularly minerals such as magnesium. Since magnesium is a very important micronutrient for the heart, diuretics can worsen the heart function if the missing vital substances are not replaced.

Acetylsalicylic acid, which is often used to thin the blood, also influences micronutrient metabolism. Acetylsalicylic acid reduces the absorption of vitamin C and increases its excretion. Vitamin C is the most important hydrophilic antioxidant and regenerates vitamin E. A lack of vitamin C can therefore lead to increased oxidation of LDL cholesterol.

-4-

Certain drugs used to reduce elevated blood fats, the CSE inhibitors, inhibit cholesterol synthesis. Since the body's own coenzyme Q10 is also synthesized via the same metabolic pathway, its synthesis is also reduced. In older people in particular, the level of coenzyme Q10 in the mitochondria decreases with age, where it is an important factor in the cell's energy production. Long-term use of CSE inhibitors without supplementing with Q10 can therefore lead to weakening of the heart muscle.

There is therefore a great need for a product that can be administered to humans to prevent nutritional deficiencies during drug treatment of diseases, particularly heart disease, in order to compensate for the increased need for vital substances due to specific disease-related deficiencies, nutritional deficiencies and/or deficiencies caused by smoking. On the other hand, there is a need for a product that does not cause harmful side effects in humans as such and/or, in combination with drugs, does not intensify the drug-related side effects but significantly reduces them through the properties of the nutritional ingredients. There is also a great need for a product that optimally compensates for the nutritional deficiencies caused by smoking and the special nutritional situations caused by smoking, such as increased need for micronutrients.

The object of the present invention is therefore to provide a means which overcomes the aforementioned disadvantages of the prior art.

This task is solved by a combination product with micronutrients such as vitamins and carotenoids, whereby the product, based on a daily dose, comprises:

- 350 - 750 mg, preferably 450 - 650 mg, more preferably 500 - 600 mg, more preferably 520 - 560 mg vitamin C;

- 100 - 200 mg, preferably 120 - 180 mg, more preferably 130 - 170 mg, more preferably 140 - 160 mg vitamin E;

- 3-25 mg, preferably 4-20 mg, preferably 5-18 mg, more preferably - 15 mg vitamin B6;

6-12 mg, preferably 7-11 mg, preferably 8-9 mg vitamin B12;

- 400 - 1000 µg, preferably 450 - 900 µg, preferably 500 - 850 µg, more preferably 600 - 800 µ% folic acid;

150 - 300 mg, preferably 160 - 250 mg, preferably 170 - 220 mg, more preferably 180 - 200 mg magnesium; 100 - 400 mg, preferably 110 - 300 mg, preferably 120 - 250 mg, more preferably 125 - 200 mg arginine;

10-20 mg, preferably 11-19 mg, preferably 12-18 mg, more preferably 15-16 mg coenzyme Q10; 2-10 mg, preferably 3-9 mg, preferably 4-8 mg, more preferably 5-6 mg carotenoids; and

- 400 - 1000 mg, preferably 420 - 900 mg, more preferably 450 - 800 mg, more preferably 500 - 600 mg Omega 3 fatty acids.

It has surprisingly been shown that a supplementary diet with the micronutrient combination product according to the invention with vitamins and carotenoids can influence the development of a heart disease and/or nutritionally support the therapy of an existing disease. Due to the properties and characteristics of the ingredients, as part of a dietary treatment together with the normal therapeutic options, the micronutrient combination product according to the invention can, for example, influence cell and tissue damage, relax the vascular muscles, improve blood circulation, optimize fat metabolism, stabilize the heart rhythm, positively influence the risk factor homocysteine and improve cardiac performance. It is particularly advantageous that the agents according to the invention in combination with drugs, for example in long-term or continuous therapy, can reduce drug-related side effects due to a drug-related special nutritional situation, for example a malnutrition situation, which can occur during the treatment of heart disease. These beneficial properties result from the special selection of the weight contents of the individual components in the product as well as from the special properties of the individual nutritional components such as vitamins, trace elements, amino acids, vitaminoids, secondary plant substances and omega-3 fatty acids.

Further advantageous embodiments of the agent according to the invention are specified in the dependent and auxiliary claims.

A preferred embodiment of the agent according to the invention additionally comprises, based on a daily dose, at least one or more substances selected from the following group:

- 2000 - 3000 IU, preferably 2150 - 2850 IU, more preferably 2250 - 2750 IU, more preferably 2500 - 2600 IU vitamin A;

4-25 mg, preferably 4-20 mg, more preferably 4-15 mg, more preferably 4-10 mg vitamin B1;

3-25 mg, preferably 4-20 mg, preferably 5-15 mg, more preferably 5-10 mg vitamin B2;

- 25 - 75 mg, preferably 30 - 70 mg, preferably 40 - 65 mg, still
preferably 50 - 60 mg niacin;

15-25 mg, preferably 16-24 mg, preferably 17-22 mg, still

preferably 18-20 mg pantothenic acid;

30 - 80 μg, preferably 35 - 75 μg, preferably 45 - 65 μg, more preferably 50 - 60 μg% selenium;

5-15 mg, preferably 6-14 mg, preferably 7-12 mg, more preferably 8-10 mg zinc;

- 40 - 80 /ig, preferably 45 - 75 /ig, more preferably 50-65 /ig, more preferably 55 - 60 /ig chromium;

- 250 - 750 mg, preferably 300 - 700 mg, preferably 400 - 650 mg, still
preferably 500 - 550 mg lysine;

- 70 - 400 mg, preferably 100 - 350 mg, preferably 150 - 300 mg, still
preferably 250 - 300 mg taurine;

50-100 mg, preferably 60 - 90 mg, preferably 65 - 85 mg, still
preferably 70 - 80 mg cystine; and/or

5-25 mg, preferably 5-20 mg, more preferably 5-15 mg, more preferably 5 - 10 mg bioflavonoids.

According to the invention, the micronutrient agent containing vitamins and carotenoids, among others, may additionally contain, based on a daily dose, at least one or more substances selected from the following group:

- 3 - 7 μg, preferably 3.5 - 6.5 μg, preferably 4.5 - 6 μg, more preferably 5 - 5.5 μg vitamin D3;

1-3 mg, preferably 1.2 - 2.8 mg, preferably 1.5 - 2.5 mg, more preferably 1.8 - 2.0 mg manganese;

- 0.5 - 1.5 mg, preferably 0.6 - 1.4 mg, preferably 0.75 - 1.25 mg, more preferably 0.8-1 mg copper;

40 - 75 /jg, preferably 45 - 70 /zg, preferably 50-65 /xg, more preferably 55 - 60 /xg molybdenum;

100 - 200 µg, preferably 110 - 180 /xg, preferably 120-170 /xg, more preferably 150 - 160 µg iodine; and/or

- 75-150 mg, preferably 80 - 140 mg, more preferably 90 - 130 mg, more preferably 100 - 120 mg inositol.

The micronutrient combination product containing vitamins and carotenoids, among others, can be in solid, liquid and/or gel form. The product is preferably in the form of tablets, capsules, powder and/or granules.

In a particularly preferred embodiment, the components of the micronutrient combination product are present in at least two separate parts, wherein the respective parts can have a different component composition.

The micronutrient combination product can comprise 0 to 10 tablets, preferably 1 to 6, preferably 1 to 5 tablets, 0 to 10 capsules, preferably 1 to 6 capsules, preferably 2 to 5 capsules, 0 to 5 solutions, preferably 1 to 2 solutions and/or 0 to 5 granules, preferably 1 to 4 granules, preferably 1 to 3 granules, wherein the respective solution(s), tablet(s), capsule(s), granule(s) and/or powder can preferably differ in their respective material composition and/or in their respective material weight proportions.

-8th-

In a preferred embodiment, the micronutrient combination product comprises at least 1 to 5 tablets, preferably 1 tablet, at least 1 to 5 capsules, preferably 4 capsules and at least 1 to 3 granules, preferably 1 granule, wherein the respective parts of the micronutrient combination product have a different component composition.

It has been shown that due to the poor miscibility of the components, particularly in aqueous solutions, a homogeneous distribution is not possible or only possible with increased effort, possibly by adding excipients. In addition, individual components can partially or even completely precipitate in solutions. Similar problems arise when the agents are administered orally, for example, individual components can settle in the mouth/throat area and/or are poorly absorbed in the gastrointestinal tract and/or reach the bloodstream with a significant delay. The aforementioned effects can lead to the individual components being absorbed in different or too low concentrations and/or at different times, which has a particularly detrimental effect on the effect.

In order to overcome these aforementioned disadvantages, the contents and substances of the individual components were selected such that after oral administration of the agent or micronutrient combination product according to the invention, an optimal blood plasma level for the respective nutritional components is established with regard to the desired effect.

According to the invention, the micronutrient product containing, among other things, vitamins and carotenoids can be present in at least two, preferably two to ten and preferably three to seven separate parts, whereby the aforementioned disadvantages can be avoided. For example, at least one part can be in solid, granular, powdery or the like and at least another part can be liquid and/or gel-like.

Advantageously, the micronutrient combination product can also comprise one and/or more tablets, capsules and/or granules with the same and/or different contents of micronutrients or vital substances.

Examples of micronutrient combination products are given below: Example 1

In the tablet/capsule micronutrient combination, the micronutrients are distributed as shown in Table I:

Table I 5 tablets/ 5 capsules

Number of tablets/capsules Micronutrients 1 multivitamin
/Trace elements capsule Vitamin B complex (vitamin
Bl, Vitamin B2, Niacin,
Vitamin B6, Vitamin B12,
Folic acid, pantothenic acid,
amino acids,
Vitamin K1, Vitamin D3,
Vitamin A, iron, zinc,
Manganese, copper, chromium,
Molybdenum, selenium 1 vitamin C film-coated tablet vitamin C 2 amino acid film-coated tablets Arginine, L-lysine, L-cystine,
Inositol, Ta.urin 1 magnesium film-coated tablet magnesium 1 iodine film-coated tablet iodine 1 Ubicarn capsule L-Carnitine, Coenzyme QlO,
nat. tocopherols, nat.
Carotenoids, citrus
Bioflavonoids 3 fish oil capsules Omega-3 fatty acids, vitamin
E

-10-

Example 2

In the granules and tablets/capsules - micronutrient combination, the micronutrients or vital substances are distributed as shown in Table II:

Table II 1 tablet/4 capsules/1 granule

Number of tablets/capsules Micronutrients 1 iodine film-coated tablet iodine 1 Ubicarn capsule L-Carnitine, Coenzyme QlO,
nat. tocopherols, nat.
Carotenoids, citrus
Bioflavonoids 3 fish oil capsules Omega-3 fatty acids, vitamin
E granules Vitamin B complex (vitamin
B1, Vitamin B2, Vitamin B6,
Vitamin B12, niacin,
Folic acid, pantothenic acid,
amino acids,
Vitamin C, Vitamin D3,
Vitamin A, magnesium,
Selenium, zinc, manganese, copper,
Chromium, molybdenum, inositol,
Taurine,
L-Arginine, L-Cystine, L-Lysine

According to the invention, the micronutrient combination product or agent may contain components that improve the availability, solubility and/or dissolution rate.

In addition, the micronutrient combination product or agent can comprise components selected from the group comprising disintegrants, substances that improve shelf life, taste-masking and/or taste-enhancing substances, substances that increase or reduce viscosity.

Furthermore, the micronutrient combination product or agent can comprise components selected from the group comprising glucose, citric acid, magnesium hydroxide, magnesium carbonate, maltodextrin, gelatin, natural flavours such as orange flavour, lactose, glycerin, cellulose, soybean oil, vegetable oil, gum arabic, lecithin, saccharin sodium, HPM cellulose, natural carmine red, magnesium stearate, titanium dioxide, microcrystalline cellulose, sorbitol, calcium hydrogen phosphate, vegetable fat, corn starch, silica, hypromellose, sodium cyclanate, iron oxide, talc, monoammonium glycerrhizinate, HP cellulose and/or aspartame.

The invention is further explained using the following examples. Example 3

Micronutrient combination product or agent containing the following active ingredients:

a. 530 mg vitamin C;

b. 150 mg vitamin E;

c. 5 mg vitamin B6;

d. 9 mg vitamin B12;

e. 800 mg folic acid;

f. 180 mg magnesium;

g. 125 mg arginine;

h. 15 mg coenzyme Q 10;

i. 200 mg carnitine;

j. 5 mg carotenoids;

k. 500 mg Omega 3 fatty acids.

The weight information, unless otherwise stated, refers to a daily dose. Example 4

Micronutrient combination product or agent according to the composition of Example 3, wherein the agent additionally comprises the following active ingredients:

1. 2500 IU vitamin A;

m. 4 mg vitamin B1;'

n. 5 mg vitamin B2;

o. 50 mg niacin;

p. 18 mg pantothenic acid;

q. 50 μg selenium;

r. 10 mg zinc;

s. 60 μg chromium;

t. 500 mg lysine;

and 300 mg taurine;

v. 80 mg cystine;

w. 5 mg bioflavonoids.

The content and weight information, unless otherwise stated, refers to a daily dose.

Example 5

Micronutrient combination product or agent comprising the components of example and 2, wherein the agent additionally comprises the following active ingredient components:

x. 5 ptg Vitamin D3;

y. 2 mg manganese;

z. 1 mg copper; aa. 60 ng molybdenum; bb. 150 mg iodine; and cc. 100 mg inositol.

-13-

The weight information, unless otherwise stated, refers to a daily dose.

Comparison example 1

Comparative Example 1 corresponds to the composition of Example 3, whereby the content of the respective components is underdosed.

Comparison example 2

Comparative Example 2 corresponds to the composition of Example 3, whereby the content of the respective components is overdosed.

Table III

ingredient Comparison example 1 Comparison example 2 Example 3 Vitamin E low
antioxidants
Effect +/-
high antioxidant
Effect, but
Inhibition of
Coagulation +
balanced
antioxidant effect Vitamin B^ Homocysteine
rise peripheral sensitive
Neuropathies +
Reduction of
Homocysteine levels Folic acid Homocysteine
rise can vitamin B 12-
Masking deficiency +
Reduction of
Homocysteine levels magnesium -/+
Shortage osmotic
Diarrhea +
no defect Carotenoids low
antioxidants
Effect High individual dose
is suspected
Lung cancer
to trigger +
balanced
antioxidant effect Coenzym
Qiao in endogenous
Shortage
Muscle weakness +/-
mild stomach
Intestinal complaints +
improves heart function
and rhythm

fs'"·"

Table III shows comparative tests with conventional vitamin preparations. It can be seen that the agents according to the invention have an improved nutritional effect with regard to heart diseases. Due to the properties and characteristics of the vitamins, minerals, trace elements, vitaminoids, secondary plant substances and the amino and fatty acids, the compositions according to the invention have an improved nutritional effect with regard to cell and tissue damage compared to conventional vitamin compositions, relax the vascular muscles for a longer period of time, lead to improved blood circulation, can optimize fat metabolism, stabilize the heart rhythm better and over a longer period of time and have a significantly more positive effect on the risk factor homocysteine.

Claims (10)

1. Micronutrient combination product characterized in that the micronutrient combination product, based on a daily dose, comprises the substances: a) 350-750 mg, preferably 450-650 mg, preferably 500-600 mg, more preferably 520-560 mg vitamin C; b) 100-200 mg, preferably 120-180 mg, preferably 130-170 mg, more preferably 140-160 mg vitamin E; c) 3-25 mg, preferably 4-20 mg, preferably 5-18 mg, more preferably 5-15 mg vitamin B6; d) 6-12 mg, preferably 7-11 mg, preferably 8-9 mg vitamin B12; e) 400-1000 µg, preferably 450-900 µg, preferably 500-850 µg, more preferably 600-800 µg folic acid; f) 150-300 mg, preferably 160-250 mg, preferably 170-220 mg, more preferably 180-200 mg magnesium; g) 100-400 mg, preferably 110-300 mg, preferably 120-250 mg, more preferably 125-200 mg arginine; h) 10-20 mg, preferably 11-19 mg, preferably 12-18 mg, more preferably 15-16 mg coenzyme Q10; i) 2-10 mg, preferably 3-9 mg, preferably 4-8 mg, more preferably 5-6 mg carotenoid; j) 400-1000 mg, preferably 420-900 mg, preferably 450-800 mg, more preferably 500-600 mg omega 3 fatty acids. 2. Micronutrient combination product according to claim 1, characterized in that the micronutrient combination product, based on a daily dose, additionally contains at least one or more substances selected from the following group: a) 2000-3000 IU, preferably 2150-2850 IU, preferably 2250-2750 IU, more preferably 2500-2600 IU of vitamin A; b) 4-25 mg, preferably 4-20 mg, more preferably 4-15 mg, more preferably 4-10 mg vitamin B1; c) 3-25 mg, preferably 4-20 mg, preferably 5-15 mg, more preferably 5-10 mg vitamin B2; d) 25-75 mg, preferably 30-70 mg, preferably 40-65 mg, more preferably 50-60 mg niacin; e) 15-25 mg, preferably 16-24 mg, preferably 17-22 mg, more preferably 18-20 mg pantothenic acid; f) 30-80 µg, preferably 35-75 µg, preferably 45-65 µg, more preferably 50-60 µg selenium; g) 5-15 mg, preferably 6-14 mg, preferably 7-12 mg, more preferably 8-10 mg zinc; h) 40-80 µg, preferably 45-75 µg, preferably 50-65 µg, more preferably 55-60 µg chromium; i) 250-750 mg, preferably 300-700 mg, preferably 400-650 mg, more preferably 500-550 mg lysine; j) 70-400 mg, preferably 100-350 mg, preferably 150-300 mg, more preferably 250-300 mg taurine; k) 50-100 mg, preferably 60-90 mg, preferably 65-85 mg, more preferably 70-80 mg cystine; and/or l) 5-25 mg, preferably 5-20 mg, more preferably 5-15 mg, more preferably 5-10 mg bioflavonoids. 3. Micronutrient combination product according to claim 1 or 2, characterized in that the micronutrient combination product, based on a daily dose, additionally contains at least one or more substances selected from the following group: a) 3-7 µg, preferably 3.5-6.5 µg, preferably 4.5-6 µg, more preferably 5-5.5 µg vitamin D3; b) 1-3 mg, preferably 1.2-2.8, preferably 1.5-2.5, more preferably 1.8-2.0 manganese; c) 0.5-1.5 mg, preferably 0.6-1.4 mg, preferably 0.75-1.25 mg, more preferably 0.8-1 mg copper; d) 40-75 µg, preferably 45-70 µg, preferably 50-65 µg, more preferably 55-60 µg molybdenum; e) 100-200 µg, preferably 110-180 µg, preferably 120-170 µg, more preferably 150-160 µg iodine; and/or f) 75-150 mg, preferably 80-140 mg, preferably 90-130 mg, more preferably 100-120 mg inositol. 4. Micronutrient combination product according to one of the preceding claims, characterized in that the micronutrient combination product is in solid, liquid and/or gel form, preferably the micronutrient combination product is in the form of at least one solution, at least one powder, at least one tablet, at least one capsule and/or at least one granulate, wherein the respective solution(s), tablet(s), capsule(s), granulate(s) and/or powder preferably differ in their respective material composition and/or in their respective material weight proportions. 5. Micronutrient combination product according to one of the preceding claims, characterized in that the micronutrient combination product comprises 0 to 10 tablets, preferably 1 to 6, preferably 2 to 5 tablets, 0 to 10 capsules, preferably 1 to 6 capsules, preferably 2 to 5 capsules, 0 to 5 solutions, preferably 1 to 2 solutions and/or 0 to 5 granules, preferably 1 to 4 granules, preferably 1 to 3 granules, wherein the respective solution(s), tablet(s), capsule(s), granule(s) and/or powder preferably differ in their respective material composition and/or in their respective material weight proportions. 6. Micronutrient combination product according to one of the preceding claims, characterized in that the micronutrient combination product contains at least one multivitamin/trace element capsule containing vitamin B complex, such as vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folic acid, pantothenic acid, biotin, vitamin K1, vitamin D3, vitamin A, iron, zinc, manganese, copper, chromium, molybdenum, selenium; at least one vitamin C film-coated tablet containing vitamin C; at least two amino acid film-coated tablets containing arginine, L-lysine, L-cystine, inositol, and taurine; at least one magnesium film-coated tablet containing magnesium, at least one iodine film-coated tablet containing iodine, at least one ubicarn capsule containing L-carnitine, coenzyme Q10, natural tocopherols, natural carotenoids and citrus bioflavonoids; and/or at least three fish oil capsules containing omega-3 fatty acids and vitamin E. 7. Micronutrient combination product according to one of the preceding claims, characterized in that the micronutrient combination product comprises at least one iodine film-coated tablet containing iodine; at least one ubicarn capsule containing L-carnitine, coenzyme Q10, tocopherols, carotenoids, citrus bioflavonoids; at least one, preferably three fish oil capsules containing omega-3 fatty acids, vitamin E; and/or at least one granulate containing vitamin B complex comprising vitamin B1, vitamin B2, vitamin B6, vitamin E12, niacin, folic acid, pantothenic acid, biotin, vitamin C and vitamin D3. 8. Micronutrient combination product according to one of the preceding claims, characterized in that the micronutrient combination product contains additives which improve the bioavailability, solubility and/or dissolution rate. 9. Micronutrient combination product according to one of the preceding claims, characterized in that the micronutrient combination product contains additives selected from the group comprising disintegrants, substances which improve the shelf life, taste-masking and/or taste-improving substances, substances for increasing or reducing the viscosity. 10. Micronutrient combination product according to one of the preceding claims, characterized in that the micronutrient combination product comprises additives selected from the group comprising glucose, citric acid, maltodextrin, gelatin, natural flavors such as orange flavor, lactose, glycerin, cellulose, soybean oil, vegetable oil, gum arabic, lecithin, saccharin sodium, HPM cellulose, natural carmine red, magnesium stearate, titanium dioxide, microcrystalline cellulose, sorbitol, calcium hydrogen phosphate, vegetable fat, corn starch, silica, hypromellose, sodium cyclanate, iron oxide, talc, monoammonium glycerrhizinate, HP cellulose, and/or aspartame.